



Efficacy of Combinations of Different Antibiotics

Guest Editor:

Dr. Josep M. Sierra

Laboratory of Molecular
Microbiology & Antimicrobials
Medical School, Department of
Pathology and Experimental
Therapeutics, University of
Barcelona, 08007 Barcelona,
Spain

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editor

Antimicrobial resistance is recognized as one of most relevant issues in public health. It is related with a high number of deaths, 70.000/year in Europe; and the perspectives are not so hopeful.

The establishment of new strategies that may reverse this scenario has become mandatory. this may be achieved by different approaches:

1. Encourage the investigation of new antimicrobials having new mechanisms of action.
2. Promote the proper use of antimicrobials
3. Stimulate the research on combination of different antimicrobials with the aim of seeking synergies between them, to increase their “in vitro” and hopefully their “in vivo” efficacy.

This special issue wants to highlight the research on different combinations of antimicrobials, whether between classic antibiotics; antibiotics and inhibitors; antimicrobials and antimicrobial peptides, or any type of combination that may have antimicrobial efficacy.

Manuscripts increasing the scientific knowledge about antimicrobial combinations either experimental or pre-clinical including “in vitro” studies, experimentation on animal models, and combinations used in routine clinical practice, are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi